New combo therapy targets Hard-to-Treat GI cancers

NCT ID NCT05274048

Recruiting now Disease control Sponsor: Fox Chase Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a combination of two drugs, neratinib and fam-trastuzumab deruxtecan (Enhertu), in people with advanced stomach, esophageal, or other gastrointestinal cancers that have a specific marker called HER2. The study aims to find the safest dose and see if the combination can shrink tumors. Participants must have already tried at least one prior treatment that stopped working or caused side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system cancer digestive system neoplasm gastric cancer gastric neoplasm gastroesophageal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER GASTROINTESTINAL CANCER HER2 GENE MUTATION

Contacts and locations

Locations

Fox Chase Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19111, United States
Roswell Park Comprehensive Cancer Center
RECRUITING

Buffalo, New York, 14263, United States
Stanford Cancer Center
RECRUITING

Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.